
Kōkua kēia alakaʻi piha iā ʻoe e hoʻomaopopo i ka maʻi maʻi maʻi maʻi renal cell carcinoma (maʻemaʻe renal cell carcinoma kokoke iaʻu) a hoʻokele i kāu mau koho no ka mālama ʻana a me ke kākoʻo. E ʻimi mākou i ka maʻi maʻi, nā ala lapaʻau, a me nā kumuwaiwai e kōkua iā ʻoe e ʻimi i ka mālama maikaʻi loa kokoke i ka home. E aʻo e pili ana i nā holomua hou loa a loaʻa nā pane i kāu mau nīnau.
ʻO ka maʻi maʻi maʻi maʻi maʻamau o ka maʻi maʻi maʻamau (ccRCC). Mai loko mai o ka ʻili o ka puʻupaʻa a hiki ke laha i nā wahi ʻē aʻe o ke kino. He mea koʻikoʻi ka ʻike mua ʻana no ka mālama pono ʻana. Hiki ke maʻalahi nā hōʻailona, e like me ke koko i loko o ka mimi, ka ʻeha o ka ʻaoʻao, a i ʻole ka palpable mass. Inā loaʻa iā ʻoe kekahi o ia mau mea, pono e ʻimi koke i ka lāʻau lapaʻau.
ʻO ka maʻi maʻamau e pili ana i nā hoʻokolohua kiʻi e like me CT scans a i ʻole MRI, me kahi biopsy e hōʻoia i ka maʻi a hoʻoholo i ka pae o ka maʻi kanesa. Hiki ke hoʻoholo i ka nui o ka laha ʻana o ka maʻi kanesa a alakaʻi i nā hoʻoholo lapaʻau. He mea koʻikoʻi ka hoʻonohonoho kūpono no ka wānana ʻana i ka wānana a me ke koho ʻana i ka hoʻolālā lapaʻau kūpono.
ʻO ka ʻoki ʻana ka lāʻau lapaʻau mua no ka ccRCC kūloko. Hiki i kēia ke komo i ka nephrectomy hapa (ka wehe ʻana i ke koko a me kahi ʻāpana liʻiliʻi o ka puʻupaʻa) a i ʻole ka nephrectomy radical (ka wehe ʻana i ka puʻupaʻa holoʻokoʻa). ʻO ke koho ma muli o ka nui a me kahi o ka ʻōpū, a me ke olakino holoʻokoʻa o ka mea maʻi.
ʻO nā lāʻau lapaʻau i hoʻopaʻa ʻia he mau lāʻau lapaʻau e kuhikuhi pono ana i nā cell cancer, e hōʻemi ana i ka pōʻino i nā cell olakino. Ua hoʻololi kēia mau lāʻau lapaʻau i ka mālama ʻana i ka ccRCC, e hāʻawi ana i nā hopena maikaʻi no nā maʻi he nui. ʻO nā laʻana he tyrosine kinase inhibitors (TKIs) e like me sunitinib, pazopanib, a me axitinib. E hoʻoholo ana kāu oncologist i ka lāʻau lapaʻau maikaʻi loa e pili ana i kāu kūlana kikoʻī.
Hoʻohana ka Immunotherapy i ka mana o ka ʻōnaehana pale o ke kino e hakakā ai i ka maʻi kanesa. Hoʻohana ʻia nā mea hoʻopaʻa hoʻopaʻa kino, e like me nivolumab a me ipilimumab, e mālama i ka ccRCC kiʻekiʻe. Ke hana nei kēia mau lāʻau lapaʻau ma ke kāohi ʻana i nā protein e pale ai i ka ʻōnaehana pale mai ka hoʻouka ʻana i nā maʻi maʻi maʻi. He maikaʻi loa lākou i kekahi mau maʻi.
Hoʻohana ka lāʻau lapaʻau i ka pāhawewe ikaika nui e pepehi i nā maʻi maʻi maʻi. ʻOiai ʻaʻole maʻamau ka lāʻau lapaʻau mua no ka ccRCC, hiki iā ia ke hana i kahi kuleana i ka mālama ʻana i nā hōʻailona a i ʻole ka mālama ʻana i nā maʻi kūloko.
ʻO ke komo ʻana i nā hoʻokolohua lapaʻau e hāʻawi i ke komo ʻana i nā lāʻau lapaʻau hou a kōkua i nā holomua i ka noiʻi maʻi maʻi. ClinicalTrials.gov (https://clinicaltrials.gov/) he kumu waiwai no ka huli ʻana i nā hoʻokolohua lapaʻau kūpono no maʻemaʻe renal cell carcinoma kokoke iaʻu.
ʻO ka ʻimi ʻana i kahi oncologist akamai i ka maʻi maʻi ʻaʻai ka mea nui. Hiki iā ʻoe ke hoʻomaka i kāu ʻimi me ka hoʻohana ʻana i nā papa kuhikuhi pūnaewele a i ʻole ke nīnau ʻana i kāu kauka mālama mua. E ʻimi i nā kauka pili i nā kikowaena maʻi maʻi kaulana. E noʻonoʻo i nā mea e like me ka ʻike, ka loea i ka mālama ccRCC, a me nā loiloi maʻi.
No ka mālama ʻana i ka maʻi maʻi maʻi, e noʻonoʻo e ʻimi i ka lāʻau lapaʻau ma kahi kikowaena kūikawā e like me ka Shandong Baofa Cancer Research Institute. Hāʻawi lākou i nā mea hana diagnostic holomua, nā koho lapaʻau ʻokiʻoki, a me kahi hui multidisciplinary e hāʻawi i ka mālama pilikino.
He mea paʻakikī ka hoʻokele ʻana i kahi hōʻailona o ccRCC. Hāʻawi nā hui kākoʻo, nā ʻaha kūkā pūnaewele, a me nā hui kākoʻo hoʻomanawanui i nā kumuwaiwai waiwai nui a me kahi kaiāulu o nā poʻe e kaʻana like i nā ʻike like. Hāʻawi ka American Cancer Society a me ka National Cancer Institute i ka ʻike nui a me nā lawelawe kākoʻo. E hoʻomanaʻo, ʻaʻole ʻoe wale nō i kēia huakaʻi.
Kuhi ʻia kēia ʻike no nā kumu hoʻonaʻauao wale nō a ʻaʻole pono e manaʻo ʻia he ʻōlelo aʻoaʻo olakino. E kūkākūkā mau me kekahi ʻoihana mālama ola kūpono no ka hōʻoia ʻana a me ka mālama ʻana i kekahi maʻi olakino.